Japanese Journal of Cancer and Chemotherapy最新文献

{"title":"[A Case of Myocardial Dysfunction in a Patient with Recurrent Colon Cancer Treated with Bevacizumab].","authors":"Takao Tamesa, Hiroki Umeno, Masahito Kinoshita, Kou Kanesada, Junya Kondo, Yoriomi Hamada, Toshikazu Gondo","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>An 86-year-old man underwent laparoscopic ileocecal resection with lymph node dissection(pT3N0M0, Stage Ⅱa, Ly1a, V1a). The patient did not receive any adjuvant chemotherapy. Two years later, the patient was diagnosed with a recurrence at the anastomotic site(RAS mutant, HER2 negative, MSI-low). After 4 courses of FOLFOX plus bevacizumab, the patient was admitted for ileus. Preoperative echocardiography revealed an ejection fraction(EF)of 35% and BNP level of 562.2 pg/ mL. Therefore, asymptomatic cardiomyopathy was suspected because of bevacizumab administration. Although the last bevacizumab dose was administered within 2 weeks, we performed a laparoscopic tumor resection with lymph node dissection. Histological examination revealed colon cancer recurrence without lymph node metastasis. The patient was discharged on 19 POD without heart failure and had no recurrence of UFT/UZEL for 11 months. Three months after surgery, EF increased to 61% and BNP level was 14 pg/mL. VEGF inhibitors are associated with a very high risk of cardiomyopathy according to the ESC guidelines(2022). These side effects in conversion therapy for cancer should be carefully considered, even though they are rare.</p>","PeriodicalId":35588,"journal":{"name":"Japanese Journal of Cancer and Chemotherapy","volume":"52 3","pages":"266-268"},"PeriodicalIF":0.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143796752","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[A Prospective Clinical Study on the Continuation Rate of Recording Electronic Patient-Reported Outcomes and Electronic Medication Notebook by Patients and the Rate of Information Reference by Attending Physicians in Cancer Chemotherapy].","authors":"Michiyo Kawai, Mamoru Hiroe, Yoshiharu Miyata, Yoichi Kurebayashi","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>This prospective observational clinical study examined the adherence of patients with cancer undergoing outpatient chemotherapy to recording Electronic Patient-Reported Outcomes(ePRO)and using electronic medication notebooks, as well as the rate of information reference by attending physicians during outpatient consultations. Among 20 patients enrolled across 3 hospitals, including Kobe University Hospital, 18 consistently maintained ePRO and electronic medication notebook entries throughout the 180-day observation period. Post-observation interviews revealed that all attending physicians referred to a summary viewer integrating ePRO and electronic medication notebook data during outpatient consultations. The integration provided physicians with a more accurate understanding of patients' daily lives in a short time. These findings provide further evidence for the usefulness of ePRO and electronic medication notebooks for monitoring the health conditions of patients with cancer outside the hospital settings.</p>","PeriodicalId":35588,"journal":{"name":"Japanese Journal of Cancer and Chemotherapy","volume":"52 3","pages":"225-229"},"PeriodicalIF":0.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143796783","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Active Surveillance and Focal Therapy in Localized Prostate Cancer from the Perspective of Organ Preservation Strategy].","authors":"Yoichiro Tohi, Mikio Sugimoto","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>While the widespread use of PSA testing has led to early detection of prostate cancer, the increased diagnosis of clinically insignificant cancers has led to overtreatment, such as prostatectomy and radiation therapy. The side effects of this overtreatment may lead to a decline in the quality of life of patients. Therefore, organ- preservation strategies for localized prostate cancer are expected to combine cancer control with functional preservation and maintenance of quality of life. In this regard, active surveillance and focal therapy are ideal concepts in organ preservation. Active surveillance is an established strategy for low-risk and some intermediate-risk prostate cancers, and focal therapy is not yet recommended as primary therapy for localized prostate cancer in various guidelines. However, focal therapy as a primary treatment targets clinically significant cancer for intervention, while active surveillance is applied to manage other insignificant cancers, potentially highlighting a compatibility between the 2 approaches. We proposed a treatment strategy in which focal therapy is performed on localized lesions and then active surveillance is continued again when disease progression is observed during active surveillance. We believe that this approach is an effective way to avoid overtreatment and to maintain the patient's quality of life for a long time. Although uniformity in diagnostic imaging quality and establishment of treatment indication criteria are needed to realize this approach, it may become a new approach to prostate cancer treatment in the future.</p>","PeriodicalId":35588,"journal":{"name":"Japanese Journal of Cancer and Chemotherapy","volume":"52 3","pages":"198-204"},"PeriodicalIF":0.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143796785","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[A Case Report-Remarkable Response of mFOLFIRINOX in Recurrent Hepatic Metastasis of Intraductal Papillary Mucinous Carcinoma(IPMC)].","authors":"Yuichi Obata, Yoshinari Maeda, Himawari Kihara, Taiki Kijima, Yoshinori Kitamura, Seiichiro Ando, Tatsuhito Yamamoto","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>A 76-year-old female presented with multiple pancreatic cystic lesions, the largest measuring 10 mm in diameter, which were identified during an examination by another department at our hospital. Following referral to our department, she underwent observation because CT scans showed that the lesions tended to enlarge. Subsequent MRCP confirmed a diagnosis of a mixed-type IPMN, prompting surgical intervention. A distal pancreatectomy with D2 lymphadenectomy was performed. Pathological examination revealed IPMC(pT1cpN0M0, pStage ⅠA). Postoperatively, the patient received adjuvant S-1 therapy. In the second year after surgery, CT and MRI revealed hepatic recurrence in segments S8(12 mm)and S5 (5 mm). mFOLFIRINOX was initiated, and after 8 courses, a follow-up CT showed the complete disappearance of both lesions, achieving a complete response(CR). mFOLFIRINOX was continued for 21 courses, without recurrence, over the subsequent year. This case highlights the efficacy of mFOLFIRINOX in treating recurrent hepatic metastases of IPMC and warrants further investigation.</p>","PeriodicalId":35588,"journal":{"name":"Japanese Journal of Cancer and Chemotherapy","volume":"52 3","pages":"263-265"},"PeriodicalIF":0.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143796782","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[A Case of Laparoscopic Splenectomy after Distal Gastrectomy for Gastric Cancer].","authors":"Junji Kawada, Minami Maruyama, Yoshitaka Okauchi, Tomonori Nomura, Yuji Ikeda, Manatsu Mizuno, Satoshi Eguchi, Yoshiki Taniguchi, Hiromitsu Hoshino, Shinya Yamashita, Hitoshi Mizuno, Yo Sasaki","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>We report a case of laparoscopic splenectomy after distal gastrectomy for gastric cancer. A 68-year-old woman underwent laparoscopic distal gastrectomy, D1+lymph node dissection and Billroth Ⅰ reconstruction for gastric cancer 5 years previously, with a final diagnosis of gastric cancer, M, Less-Ant, 0-Ⅱa, pT1b(SM), pN1(2/52), H0, P0, M0, pStage ⅠB(HER2 IHC 3+). Three years and 6 months after gastrectomy, CT scan showed a splenic tumor, and PET scan also showed FDG accumulation. Diagnosed as splenic metastasis post-gastric cancer surgery, she underwent chemotherapy with S-1, cisplatin, and trastuzumab. After 1 year and 6 months of chemotherapy, the splenic tumor showed mild shrinkage but persisted, leading to the decision for splenectomy due to difficulties in continuing chemotherapy. After laparoscopic splenectomy, intraoperative ICG fluorescence imaging confirmed blood flow in the remaining stomach, so the remnant stomach was preserved. No ischemic complications were observed postoperatively. The final pathology revealed an inflammatory pseudotumor of the spleen, and the patient is under observation. This case highlights successful management of a splenic tumor following distal gastrectomy with preservation of the remnant stomach using laparoscopic splenectomy and intraoperative ICG fluorescence imaging.</p>","PeriodicalId":35588,"journal":{"name":"Japanese Journal of Cancer and Chemotherapy","volume":"52 3","pages":"272-274"},"PeriodicalIF":0.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143796727","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[A Case of Recurrent Tracheal Adenoid Cystic Carcinoma Treated with Multidisciplinary Therapy].","authors":"Yasuki Hachisuka, Masashi Uomoto","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Tracheal adenoid cystic carcinoma(TACC)is relatively rare. Therapy for recurrent TACC has not yet been established. A woman in her late 80s was diagnosed with TACC just below the vocal folds. At the same time, a solitary lung metastasis in the right upper lobe was detected on admission. After tracheal tumor resection using rigid bronchoscopy, radiation therapy 40 Gy was administered. Subsequently, right upper lobectomy was performed. Two years after first admission(FA), radiation therapy 35 Gy for tracheal recurrence was performed. Two years and 6 months after FA, wedge resection was performed for metastases to the left lung. Three years after FA, multiple bilateral lung metastases were detected, and pembrolizumab was administered. Four years after FA, bloody sputum due to local tracheal recurrence was observed, and photodynamic therapy was initiated. Six years after FA, tracheostomy and tracheal cauterization under rigid bronchoscopy were performed for airway stenosis. At that time(7 years after FA), the patient was undergoing second-line chemotherapy. We report a case of recurrent TACC treated with multidisciplinary therapy.</p>","PeriodicalId":35588,"journal":{"name":"Japanese Journal of Cancer and Chemotherapy","volume":"52 3","pages":"231-233"},"PeriodicalIF":0.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143796761","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[The Role of Kidney-Sparing Surgery for Patients with Upper Tract Urothelial Carcinoma].","authors":"Satoshi Katayama, Kasumi Yoshinaga, Tatsushi Kawada, Takuya Sadahira, Yusuke Tominaga, Takehiro Iwata, Shingo Nishimura, Kensuke Bekku, Tomoko Kobayashi, Kohei Edamura, Motoo Araki","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>With the advancement of modern ureteroscopes and laser technology, kidney-sparing surgery(KSS)has an expanding role for patients with upper tract urothelial carcinoma(UTUC), although radical nephroureterectomy remains the gold standard. Patients with UTUC are generally elderly and often have major medical comorbidities. As such, KSS is recommended for patients with imperative indications, such as bilateral disease, renal insufficiency, or a solitary kidney, while maintaining renal function, resulting in the avoidance of potential long-term cardiovascular morbidity and hemodialysis. In addition, KSS is also advocated for low-risk patients(elective indication)based on the risk stratifications recommended by each guideline. The big issue of risk stratifications is their narrow indications at the cost of providing accuracy, but the current elective indications have been updated and expanded year by year. KSS includes endoscopic management through antegrade or retrograde access to the upper tract and segmental ureterectomy. Thulium: YAG laser in combination with Ho: YAG laser is recently used for KSS due to the advantages of its shallow penetration depth in tissue, with a reduced risk of upper urinary tract perforation. The concern regarding KSS is a high recurrence rate. Adjuvant intracavitary instillation to the upper tract has the potential to reduce the risk of recurrence. The phase Ⅲ trial assessing a mitomycin-containing reverse thermal gel (JelmytoTM)revealed the promising result despite their use not being approved in Japan. Therefore, KSS is assumed to have an increasing demand for patients with UTUC in our aged society and is expected to be widely utilized nationwide.</p>","PeriodicalId":35588,"journal":{"name":"Japanese Journal of Cancer and Chemotherapy","volume":"52 3","pages":"210-216"},"PeriodicalIF":0.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143796748","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[A Case of Descending Colon Cancer Resulting in Cecal Perforation and Necrosis of the Large Intestine Due to Obstructive Colitis].","authors":"Ryoji Kamei, Taro Hamasaki, Hiroki Umeno, Hiroki Nakatsu","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>An 81-year-old woman had been constipated for a week and experienced nausea and decreased appetite 3 days earlier. She developed chills and general fatigue and was referred to our department. A plain abdominal computed tomography (CT)scan showed wall thickening of the descending colon, the oral side of the intestine was significantly dilated and filled with fecal masses, the anal side of the intestine was collapsed, and ascites and free air were present. Emergency surgery was performed. The area from the cecum to the descending colon was markedly dilated, and a tumor was identified in the descending colon. Fecal fluid leaked from 2 locations on the anterior wall of the cecum, and the walls from the cecum to the ascending colon were poorly colored and necrotic. The necrotic intestine was resected, and an ileostomy and transverse colon mucous fistula were constructed. Radical surgery was performed 26 days after the surgery. Invasion of the transverse colon by descending colon cancer was suspected; therefore, we performed resection from the transverse colon to the sigmoid colon, D3 dissection, and transverse colon-sigmoid colon anastomosis. After adjuvant chemotherapy, the ileostomy and mucous fistula were closed. Nearly 3 years have passed since the radical surgery, and the patient is currently under follow-up with no recurrence.</p>","PeriodicalId":35588,"journal":{"name":"Japanese Journal of Cancer and Chemotherapy","volume":"52 3","pages":"246-248"},"PeriodicalIF":0.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143796685","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[A Case of Long-Term Prognosis of Advanced Rectosigmoid Cancer with Multiple Metastases Treated with Multidisciplinary Therapy].","authors":"Yasutaka Shimada, Tetsuro Ikeya, Masato Satake, Kuniyasu Murahashi","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>The case was 50-year-old woman, who was diagnosed with advanced rectosigmoid cancer with multiple liver metastases and solitary lung metastasis. She was started with chemotherapy. Two courses of mFOLFOX6+panitumumab and 8 courses of mFOLFOX6+bevacizumab were administered as a first-line. As a second-line, 1 course of FOLFIRI+ramucirumab was given. Six months later, CT showed that lung metastasis had disappeared and all liver metastases had become smaller, therefor surgery was selected. Laparoscopic partial hepatectomy was performed, and 2 months later, laparoscopic high anterior resection was added. She received 4 courses of capecitabine as adjuvant chemotherapy, but the lung metastasis had enlarged, and thoracoscopic partial lung resection was performed. Five months later, a nodule suspected metastasis was noted on the dissected surface of liver S5 on CT, and a right liver lobectomy was added. She was surviving for 2 years and 10 months after diagnosis of Stage Ⅳ rectal cancer, and had been progression-free for 10 months after last treatment.</p>","PeriodicalId":35588,"journal":{"name":"Japanese Journal of Cancer and Chemotherapy","volume":"52 3","pages":"243-245"},"PeriodicalIF":0.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143796733","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Histologic Types of Peritoneal Disease in Pseudomyxoma Peritonei as Prognostic Factor.","authors":"Yutaka Yonemura, Haruaki Ishibashi, Akiyoshi Mizumoto, Takuji Fujita, Yang Liu, Satoshi Wakama, Sachio Fushida, Shouzou Sako, Nobuyuki Takao, Toshiyuki Kitai, Yasuo Hirono, Keizou Taniguchi, Daisuke Fujimoto, Rei Noguchi, Shizuki Takemura","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>The present study aims the prognostic significance of the histologic classification of peritoneal disease of pseudomyxoma peritonei(PMP)from appendix.</p><p><strong>Patients: </strong>During the last 15 years, 1,117 patients were histologically diagnosed for primary and peritoneal disease components according to the new WHO classification by Carr. Primary appendiceal tumors are classified into low grade appendiceal mucinous neoplasm(LAMN), high grade appendiceal mucinous neoplasm(HAMN), and mucinous neoplasm with signet ring cell carcinoma(Sig). The histologic types of peritoneal disease components were classified into four groups, ie, acellular mucin(AM), mucinous carcinoma peritonei with low grade histologic feature(LGMCP), that with high grade histologic type(HGMCP), high grade mucinous carcinoma peritonei with signet ring cells(HGMCP-S).</p><p><strong>Results: </strong>Among 1,117 primary tumors, 834(74.7%), 221(19.8%), and 62(5.5%)shows LAMN, HAMN and Sig, respectively. Histologic types of peritoneal disease from LAMN changed to AM, HGMCP, and HGMCP-S. were found in 251 (30.1%), 173(20.7%), and 19(2.3%), respectively. Among 221 patients with HAMN, histologic type of peritoneal disease changed to AM, LGMCP, and HGMCP-S in 12(5.4%), 15(6.8%)and 35(15.8%), respectively, Among 62 patients whose primary tumors were Sig, 4(6.5%), 5(8.1%), and 5(8.1%)showed AM, LGMCP, and HGMCP, respectively. Patients with AM shows the best survival curves with 10 year-survival rate of 86.9%. The 10-year survival rates of LGMCP, HGMCP, and HGMCP-S were 63.7%, 32.2%, and 10.1%, respectively(p=0.00023). In patients with primary tumor showing LAMN, the 10-year survival rates of AM, LGMCP, HGMCP, and HGMCP-S of peritoneal disease were 91.9%, 73.2%, 49.6%, and 23.9%, respectively(p<0.0001). In patients with primary tumor showing HAMN without signet ring cell component, the 10-year survival rates of AM or LGMCP and HGMCP or HGMCP-S were 58.6%, and 21.6%, respectively(p<0.001). In patients with primary tumor having signet ring cell component, 10-year survival rates of AM or LGMCP and HGMCP or HGMCP-S were 61.3% and 19.4%, respectively.</p><p><strong>Conclusions: </strong>Postoperative survival of patients with PMP significantly correlates with pathologic features of peritoneal disease. Accordingly, CRS should be performed after the intraoperative pathologic diagnosis of peritoneal disease.</p>","PeriodicalId":35588,"journal":{"name":"Japanese Journal of Cancer and Chemotherapy","volume":"52 3","pages":"275-278"},"PeriodicalIF":0.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143796762","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}